A highly specific HER3 rabbit monoclonal antibody (mAb) developed by use-based Cell Signaling Technology could provide important new information for researchers studying HER2-mediated breast, lung and ovarian tumours.
Although HER2 has been intensively studied for more than 20 years, it has only recently emerged that HER3 may be required for HER2 transformation of normal cells in at least a subset of cancers.
Preclinical research has also recently shown that HER3 activity may be a mechanism that involves tumour cells escaping inhibition.
CST’s HER3 antibody is a rabbit monoclonal and therefore avoids well-known background issues when using mouse antibodies for IHC in mouse xenograft models, which predominate in cancer research.
In addition, extensive testing has confirmed that there is no cross-reactivity with other family members, including EGFR HER2/ErbB2 and HER4/ErbB4 enabling greater confidence in research results.
Using innovative proteomic technologies the study and analysis of the cancer proteome has identified the EML4-ALK fusion, which has been reported in a subset of patients with breast colon and non-small cell lung cancer (NSCLC).
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below formBy GlobalData
Founded by research scientists in 1999, Cell Signaling Technology (CST) is a private, family owned company with more than 400 employees worldwide.
Image: Rabbit monoclonal antibodies avoids well-known background issues assocated with mice antibodies. Photo: courtesy of Cell Signalling Technology.